Shanghai NovoMix Biotechnology Co., Ltd.

DUBLIN, Nov. 30, 2022 /PRNewswire/ -- The "Insulin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type and Geography" report has been added to ResearchAndMarkets.com's offering. The insulin market is projected to grow from US$ 54,611.42 million in 2021 to US$ 111,213.73 million by 2028. It is expected to grow at a CAGR of 10.8 % from 2022 to 2028. The increase in the incidence of diabetes and rapid technological developments in insulin delivery devices by major players is expected to bolster the insulin market in the years to come. Additionally, the regeneration of the diabetic pancreas with advanced transplants is likely to emerge as a significant future trend in the insulin market from 2022 to 2028. However, the risks associated with insulin delivery devices hamper the overall market growth. In diabetic people, the pancreas does not produce enough insulin, or the body does not usually respond to the insulin, increasing the blood glucose level. Insulin is a hormone that helps in lowering blood sugar levels. Insulin therapy is often an essential part of diabetes treatment. It is made by the beta cells of the pancreas and released into the blood when glucose levels rise, for example, after eating. Insulin helps glucose get into the body cells, which can be used for energy or stored for future use. Different types of insulin available vary in how quickly and for how long they can control blood sugar. Insulin does not come in pill form as the digestive system would break it down before it could work. Insulin therapy is exhausting; however, it is an effective way of lowering blood sugar levels. Products with advanced insulin technology with more benefits are a major requirement in treating diabetes. There has been a rise in advancements in diabetes treatment over the past few years. As the prevalence of diabetes is increasing worldwide, the demand for advanced products is also boosting. The insulin market is expected to grow owing to an increase in the strategic efforts made by the industry players. The market players actively support their public and private research and academic institutes for increasing research activities. A few of the recent developments related to rapid technological advancement in the insulin market are mentioned below: In May 2022, Eli Lilly and Company received US FDA approval for its Mounjar (tirzepatide) once-weekly Glucose-Dependent Insulinotropic Polypeptide (GIP) and GLP-1 Glucagon-like Peptide-1 (GLP-1) receptor agonist for the treatment of adults with type 2 diabetes. The injection is decided to be available in 6 doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg) as an auto-injector pen with a preattached hidden needle. Key Topics Covered: 1. Introduction 2. Insulin Market - Key Takeaways 3. Research Methodology 4. Insulin Market - Market Landscape 4.1 Overview 4.2 PEST Analysis 4.2.1 North America- PEST Analysis 4.2.2 Europe- PEST Analysis 4.2.3 Asia Pacific- PEST Analysis 4.2.4 Middle East & Africa- PEST Analysis 4.2.5 South & Central America- PEST Analysis 4.2.6 Expert Opinion 5. Insulin Market- Key Market Dynamics 5.1 Market Drivers 5.1.1 Increase in Incidence of Diabetes 5.1.2 Rapid Technological Developments in Insulin Delivery Devices by Major Players 5.2 Market Restraints 5.2.1 Risks Associated with Insulin Delivery Devices 5.3 Market Opportunities 5.3.1 Insufficient Competition from Biosimilars 5.4 Future Trends 5.4.1 Regeneration of Diabetic Pancreas with Advanced Transplants 5.5 Impact Analysis 6. Insulin Market- Global Analysis 6.1 Global Insulin Market Revenue Forecast and Analysis 6.1.1 Global Insulin Market, By Geography - Forecast and Analysis 6.1.2 Global Insulin Market - Market Potential Analysis, By Region 6.2 Company Analysis 6.2.1 Market Positioning of Key Players 6.2.2 Comparative Company Analysis 6.2.3 Growth Strategy Analysis 6.2.4 Performance Of Key Players 6.2.4.1 Novo Nordisk A/S 6.2.4.2 Sanofi 6.2.4.3 Eli Lily and Company 6.3 Customization Part 6.3.1 Market Share Analysis by Company 6.3.2 Market Share by Injectable GLPs 7. Insulin Market Analysis - By Type 7.1 Overview 7.2 Insulin Market Revenue Share, by Type (2021 and 2028) 7.3 Long Acting Insulin 7.3.1 Overview 7.3.2 Long Acting Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.3.2.1 Levemir 7.3.2.1.1 Overview 7.3.2.1.2 Levemir: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.3.2.2 Lantus 7.3.2.2.1 Overview 7.3.2.2.2 Lantus: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.3.2.3 Basaglar 7.3.2.3.1 Overview 7.3.2.3.2 Basaglar: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.3.2.4 Tresiba 7.3.2.4.1 Overview 7.3.2.4.2 Tresiba: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.4 Rapid Acting Insulins 7.4.1 Overview 7.4.2 Rapid Acting Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.4.2.1 Novolog 7.4.2.1.1 Overview 7.4.2.1.2 Novolog: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.4.2.2 Humalog 7.4.2.2.1 Overview 7.4.2.2.2 Humalog: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.4.2.3 Admelog 7.4.2.3.1 Overview 7.4.2.3.2 Admelog: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.4.2.4 Others 7.4.2.4.1 Overview 7.4.2.4.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.5 Short Acting Insulins and Traditional Human Insulins 7.5.1 Overview 7.5.2 Short Acting Insulins and Traditional Human Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.5.2.1 Novolin R 7.5.2.1.1 Overview 7.5.2.1.2 Novolin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.5.2.2 Humulin R 7.5.2.2.1 Overview 7.5.2.2.2 Humulin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.5.2.3 Insuman 7.5.2.3.1 Overview 7.5.2.3.2 Insuman: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.5.2.4 Others 7.5.2.4.1 Overview 7.5.2.4.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.6 Concentrated Insulins and Combination Insulins 7.6.1 Overview 7.6.2 Concentrated Insulins and Combination Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.6.2.1 NovoMix 7.6.2.1.1 Overview 7.6.2.1.2 NovoMix: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.6.2.2 Ryzodeg 7.6.2.2.1 Overview 7.6.2.2.2 Ryzodeg: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.6.2.3 Xultophy 7.6.2.3.1 Overview 7.6.2.3.2 Xultophy: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.6.2.4 Soliqua/Suliqua 7.6.2.4.1 Overview 7.6.2.4.2 Soliqua/Suliqua: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.7 Biosimilar Insulins 7.7.1 Overview 7.7.2 Biosimilar Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.7.2.1 Insulin Glargine 7.7.2.1.1 Overview 7.7.2.1.2 Insulin Glargine: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.7.2.2 Human Insulin 7.7.2.2.1 Overview 7.7.2.2.2 Human Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.8 Glucagon-like peptide-1 (GLP-1) 7.8.1 Overview 7.8.2 Glucagon-like peptide-1 (GLP-1): Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.9 Pens and Needles 7.9.1 Overview 7.9.2 Pens and Needles: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.10 Others 7.10.1 Overview 7.10.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 8. Global Insulin Market - Geographic Analysis 9. Impact of COVID-19 Pandemic on Global Insulin Market 9.1 North America: Impact Assessment of COVID-19 Pandemic 9.2 Europe: Impact Assessment of COVID-19 Pandemic 9.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic 9.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic 9.5 South and Central America: Impact Assessment of COVID-19 Pandemic 10. Insulin Market-Industry Landscape 10.1 Overview 10.2 Growth Strategies in the Insulin Market (%) 10.3 Organic Developments 10.3.1 Overview 10.4 Inorganic Developments 10.4.1 Overview 11. Company Profile 11.1 Eli Lilly and Company 11.1.1 Key Facts 11.1.2 Business Description 11.1.3 Products and Services 11.1.4 Financial Overview 11.1.5 SWOT Analysis 11.1.6 Key Developments 11.2 Novo Nordisk A/S 11.2.1 Key Facts 11.2.2 Business Description 11.2.3 Products and Services 11.2.4 Financial Overview 11.2.5 SWOT Analysis 11.2.6 Key Developments 11.3 Biocon 11.3.1 Key Facts 11.3.2 Business Description 11.3.3 Products and Services 11.3.4 Financial Overview 11.3.5 SWOT Analysis 11.3.6 Key Developments 11.4 WOCKHARDT 11.4.1 Key Facts 11.4.2 Business Description 11.4.3 Products and Services 11.4.4 Financial Overview 11.4.5 SWOT Analysis 11.4.6 Key Developments 11.5 Adocia 11.5.1 Key Facts 11.5.2 Business Description 11.5.3 Products and Services 11.5.4 Financial Overview 11.5.5 SWOT Analysis 11.5.6 Key Developments 11.6 GlaxoSmithKline plc. 11.6.1 Key Facts 11.6.2 Business Description 11.6.3 Products and Services 11.6.4 Financial Overview 11.6.5 SWOT Analysis 11.6.6 Key Developments 11.7 Sanofi 11.7.1 Key Facts 11.7.2 Business Description 11.7.3 Products and Services 11.7.4 Financial Overview 11.7.5 SWOT Analysis 11.7.6 Key Developments 11.8 Pfizer Inc. 11.8.1 Key Facts 11.8.2 Business Description 11.8.3 Products and Services 11.8.4 Financial Overview 11.8.5 SWOT Analysis 11.8.6 Key Developments 11.9 Merck & Co., Inc. 11.9.1 Key Facts 11.9.2 Business Description 11.9.3 Products and Services 11.9.4 Financial Overview 11.9.5 SWOT Analysis 11.9.6 Key Developments 11.10 Tonghua Dongbao Pharmaceutical Co., Ltd. 11.10.1 Key Facts 11.10.2 Business Description 11.10.3 Products and Services 11.10.4 Financial Overview 11.10.5 SWOT Analysis 11.10.6 Key Developments 11.11 BIGFOOT BIOMEDICAL, INC. 11.11.1 Key Facts 11.11.2 Business Description 11.11.3 Products and Services 11.11.4 Financial Overview 11.11.5 SWOT Analysis 11.11.6 Key Developments 12. Appendix For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

December 10, 2015 By Dan Emerson, BioSpace.com News Based in North Carolina’s Research Triangle Park, NovaTarg Therapeutics is a small, early-stage company with a lot of potential. NovaTarg recently got a jump start when the National Institutes of Health authorized two grants, which totaled $3.2 million, to develop drug candidates for polycystic kidney disease and Type 2 diabetes. NovaTarg was founded in 2009 by former GlaxoSmithKline executive Ken Batchelor with the mission to discover and develop new, more effective molecularly-targeted therapies and companion molecular diagnostics to treat metabolic diseases and cancer. BioSpace spoke with Chief Executive Officer Ken Batchelor about NovaTarg’s drug development plans and prospects. Competition Batchelor told BioSpace he expects to announce NovaTarg’s first drug candidates by the middle of next year. NovaTarg ‘s work focuses on adenosine monophosphate-activated protein kinase (AMPK), an enzyme that plays a role in cellular energy homeostasis. “A number of people are working on AMPKs, but we don’t know of anyone else who is doing the same thing as us. We are positioned well to deliver drugs for these indications,” Batchelor said. According to Batchelor , the market for Type 2 diabetes is highly competitive and diversified with 394 drugs in active development. “The distribution of pipeline programs is not skewed strongly toward any one stage of development, indicating a continuing unmet medical need in this therapeutic area. Also, new drugs are being developed across a wide range of compound classes and, while none is taking the same approach as NovaTarg , some are looking at AMPK activators,” he said. The top-selling diabetes drugs in 2014 were: Novo Nordisk ’s Novolog (includes NovoRapid Novolog $17.45 billion and NovoMix Novolog $9.87 billion), $27.32 billion; Sanofi Aventis ’ Lantus, $6.34 billion; Merck & Co. ’s Januvia/Janumet, $6 billion; and Lilly ’s Humalog, $2.79 billion. NovaTarg’s Target in Focus Batchelor had worked with AMPK activators while he was a senior VP of drug discovery at GlaxoSmithKline , a position he held for 10 years. “I just knew this was a very important area for drug discovery,” he told BioSpace . “Pharmaceutical companies had been looking for drugs with this activity for a long time without much success. I realized, ‘This is the “Holy Grail.’” NovaTarg is expanding on research mostly being done in Paris, Batchelor noted. “We found a very neat way of activating AMPK, largely through targeting mitochondria,” he said.AMPK is important because “it has so many applications for a variety of metabolic diseases such as Type 2 diabetes and polycystic kidney disease,” Batchelor explained. “Both of these are profoundly affected by AMPK.” NovaTarg’s Leaders While at GlaxoSmithKline , Batchelor was co-inventor of Avodart, a blockbuster drug for the treatment of BPH. During his 30-plus year career, Batchelor also played a significant role in the discovery and development of a number of drugs for the treatment of cancer, metabolic disease and viral diseases. The NovaTarg executive team also includes two other former GlaxoSmithKline executives, Vice President of Drug Discovery Jeff Cobb and Vice President of Biology Nick Livingston . Will Seek Financing Next Year Batchelor said the grants will finance NovaTarg ‘s initial preclinical work and he plans to begin seeking Series A financing in mid-2016. NovaTarg will generate revenue through sales and co-marketing of its therapeutic and diagnostic products, as well as royalties generated from corporate partners who license its discovery tools for their internal programs, Batchelor said. For pharma companies, diabetes represents a potentially huge market; some analysts estimate that taking just 1 percent of the market could translate into $1 billion or more in annual sales. What to Watch For Batchelor said NovaTarg is working on identifying its initial drug targets for Type 2 diabetes and polycystic kidney disease “entirely in parallel. At this point, we can’t tell which would come first. But, by the middle of next year we should be at the candidate stage.”